175 related articles for article (PubMed ID: 9085140)
1. Receptor scintigraphy of non-neuroendocrine cancers with In-111 pentetreotide.
Limouris GS; Rassidakis A; Kondi-Paphiti A; Triantafyllou N; Manetou A; Gennatas K; Vitoratos N; Gregoriou O; Stavraka A; Vlahos L
Hybridoma; 1997 Feb; 16(1):133-7. PubMed ID: 9085140
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide.
Limouris GS; Rassidakis A; Kondi-Paphiti A; Triantafyllou N; Manetou A; Giannakopoulos V; Toubanakis N; Psyhojios I; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1593-7. PubMed ID: 9179200
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography.
Albérini JL; Meunier B; Denzler B; Devillers A; Tass P; Dazord L; Le Simple T; Laissue J; de Jong R; Le Cloirec J; Reubi JC; Bourguet P
Breast Cancer Res Treat; 2000 May; 61(1):21-32. PubMed ID: 10930087
[TBL] [Abstract][Full Text] [Related]
4. Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallium-201 SPECT and MRI.
Lee JD; Kim DI; Lee JT; Chang JW; Park CY
J Nucl Med; 1995 Apr; 36(4):537-41. PubMed ID: 7699438
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of somatostatin receptor scintigraphy with indium-111 pentetreotide in small-cell bronchial carcinoma].
Hoefer M; Schmidt S; Welter J; Kirsch CM; Ukena D; Sybrecht GW
Pneumologie; 1998 Feb; 52(2):106-12. PubMed ID: 9557059
[TBL] [Abstract][Full Text] [Related]
6. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.
Asnacios A; Courbon F; Rochaix P; Bauvin E; Cances-Lauwers V; Susini C; Schulz S; Boneu A; Guimbaud R; Buscail L
J Clin Oncol; 2008 Feb; 26(6):963-70. PubMed ID: 18281671
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
[TBL] [Abstract][Full Text] [Related]
9. 111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance.
Genestreti G; Bongiovanni A; Burgio MA; Burgio SL; Musto A; Rossi A; Monti M; Scarpi E; Ulivi P; Bravaccini S; Dubini A; Matteucci F; Gavelli G
Nucl Med Commun; 2015 Feb; 36(2):135-42. PubMed ID: 25321157
[TBL] [Abstract][Full Text] [Related]
10. Radiolabelled somatostatin analogue scintigraphy in oncology.
O'Byrne KJ; Carney DN
Anticancer Drugs; 1996 Jan; 7 Suppl 1():33-44. PubMed ID: 8822083
[TBL] [Abstract][Full Text] [Related]
11. Radiolabelled somatostatin analogs for diagnosis and radio-guided surgery of neuroendocrine breast cancer undetectable with conventional imaging procedures.
Panareo S; Carcoforo P; Lanzara S; Corcione S; Bagatin E; Casali M; Costanzo A; Basaglia E; Feggi LM
Breast; 2008 Feb; 17(1):111-4. PubMed ID: 17869107
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
13. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
[TBL] [Abstract][Full Text] [Related]
15. Dynamic indium-111-pentetreotide scintigraphy in breast cancer.
Bajc M; Ingvar C; Palmer J
J Nucl Med; 1996 Apr; 37(4):622-6. PubMed ID: 8691252
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
17. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
18. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.
Cuccurullo V; Di Stasio GD; Mansi L
Nucl Med Rev Cent East Eur; 2017; 20(1):49-56. PubMed ID: 28218348
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas.
Lugtenburg PJ; Löwenberg B; Valkema R; Oei HY; Lamberts SW; Eijkemans MJ; van Putten WL; Krenning EP
J Nucl Med; 2001 Feb; 42(2):222-9. PubMed ID: 11216520
[TBL] [Abstract][Full Text] [Related]
20. Intraoperative gamma probe detection of neuroendocrine tumors.
Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
